Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Seed VC - II | Alive

Total Raised


Last Raised

$890K | 10 mos ago

About InterShunt Technologies

InterShunt designs and develops a catheter-based, minimally-invasive procedure to provide relief for people suffering from heart failure.

InterShunt Technologies Headquarters Location

3650 Annapolis Lane N. Suite 160

Minneapolis, Minnesota, 55447,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing InterShunt Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

InterShunt Technologies is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,491 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

InterShunt Technologies Patents

InterShunt Technologies has filed 8 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiology
  • Cardiovascular physiology
patents chart

Application Date

Grant Date


Related Topics




Cardiac anatomy, Congenital heart defects, Cardiovascular physiology, Cardiology, Embryology of cardiovascular system


Application Date


Grant Date



Related Topics

Cardiac anatomy, Congenital heart defects, Cardiovascular physiology, Cardiology, Embryology of cardiovascular system



Latest InterShunt Technologies News

InterShunt Technologies Announces Expansion of Board of Directors and Opening of Minneapolis Facility

Feb 9, 2021

News provided by Share this article PLYMOUTH, Minn., Feb. 9, 2021 /PRNewswire/ -- InterShunt Technologies, Inc., an early-stage medical device company developing a novel catheter-based solution to reduce left atrial pressure in heart failure patients, announced today the appointment of key members to the company's Board of Directors. Jim Bullock, David Adair, MD, MBA, and Denis Harrington join current Board Directors Harlee Sorkin, CEO and InterShunt Founder Gil Vardi, MD. Jim Bullock, a veteran in the medical device industry brings extensive experience with early-stage companies. Jim has served as President and Chief Executive Officer of Zyga Technology (acquired by RTI Surgical), Atritech (acquired by Boston Scientific) and Endocardial Solutions (acquired by St. Jude Medical). He began his career at American Hospital Supply, which was later acquired by Baxter Healthcare and currently is a Board Director for a number of public and private medical device companies. We're grateful to have such well-respected industry leaders as Jim Bullock, David Adair and Denis Harrington join our team. David Adair, MD, MBA, Managing Partner of Solas BioVentures, is an experienced entrepreneur and Board Director. David is board certified in Maternal-Fetal Medicine, Obstetrics and Gynecology and Hypertension with special expertise in Critical Care. He was a founding member of Solas BioVentures in 2014 and focuses on investments in medical device and therapeutic companies. Denis Harrington, a seasoned executive in the med tech arena, has served as President and CEO of NexGen Medical Systems and BridgePoint Medical (acquired by Boston Scientific & Covidien). Prior to this, Denis spent 18 years with Boston Scientific in cardiovascular sales and executive management roles. He is currently a Board Director and Consultant for a number of medical device and technology companies. Denis will serve as Chairman of the Board. Harlee Sorkin, CEO of InterShunt expressed, "We're grateful to have such well-respected industry leaders as Jim, Dave & Denis join our team. Their experience developing trans-catheter cardiovascular solutions and bringing them to market is an ideal fit with our needs at this stage. In addition to expanding our Board, we have established a facility in Plymouth, MN that allows us to leverage the Minneapolis ecosystem that is rich with med tech talent and resources. We believe these developments all come together to accelerate our program." About InterShunt Technologies, Inc. InterShunt is developing a proprietary catheter system that allows for the capture and excision of tissue from the interatrial septum. The result is a left to right atrial shunt that off-loads elevated left atrial pressure, reducing symptoms in Heart Failure patients. The mechanical system is designed for safety and ease of use and is the only interatrial shunting device that requires no implant and no energy. For more information please visit . SOURCE Inter Shunt

InterShunt Technologies Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

InterShunt Technologies Rank

  • When was InterShunt Technologies founded?

    InterShunt Technologies was founded in 2015.

  • Where is InterShunt Technologies's headquarters?

    InterShunt Technologies's headquarters is located at 3650 Annapolis Lane N., Minneapolis.

  • What is InterShunt Technologies's latest funding round?

    InterShunt Technologies's latest funding round is Seed VC - II.

  • How much did InterShunt Technologies raise?

    InterShunt Technologies raised a total of $4.02M.

  • Who are the investors of InterShunt Technologies?

    Investors of InterShunt Technologies include Solas Bioventures and gBETA.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.